Reporting of Sociodemographic Data in Cochlear Implant Clinical Trials: A Systematic Review

Meinhardt, Gerek; Sharrer, Christine; Perez, Nicole; Downes, Alexandra; Davidowitz, Tess; Schuh, Marissa; Robinson, Lauren; Lustig, Lawrence R.; Bush, Matthew L.

doi:10.1097/mao.0000000000003766

Cited by 10 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…52 It is unknown if or how this translates to skin pigmentation. These racial and ethnic ARHL prevalence estimates may not be accurate due to longstanding inequitable access to hearing care, 43 underreporting of sociodemographic data of participants in hearing research, 53 and underrepresentation in hearing-related clinical trials 54 among some populations.…”

Section: Health Care Burden Epidemiologymentioning

confidence: 99%

Clinical Practice Guideline: Age‐Related Hearing Loss Executive Summary

Tsai Do,

Bush,

Weinreich

et al. 2024

Otolaryngol.--head neck surg.

View full text Add to dashboard Cite

ObjectiveAge‐related hearing loss (ARHL) is a prevalent but often underdiagnosed and undertreated condition among individuals aged 50 and above. It is associated with various sociodemographic factors and health risks including dementia, depression, cardiovascular disease, and falls. While the causes of ARHL and its downstream effects are well defined, there is a lack of priority placed by clinicians as well as guidance regarding the identification, education, and management of this condition.PurposeThe purpose of this clinical practice guideline is to identify quality improvement opportunities and provide clinicians trustworthy, evidence‐based recommendations regarding the identification and management of ARHL. These opportunities are communicated through clear actionable statements with an explanation of the support in the literature, the evaluation of the quality of the evidence, and recommendations on implementation. The target patients for the guideline are any individuals aged 50 years and older. The target audience is all clinicians in all care settings. This guideline is intended to focus on evidence‐based quality improvement opportunities judged most important by the Guideline Development Group (GDG). It is not intended to be a comprehensive, general guide regarding the management of ARHL. The statements in this guideline are not intended to limit or restrict care provided by clinicians based on their experience and assessment of individual patients.Action StatementsThe GDG made strong recommendations for the following key action statements (KASs): (KAS 4) If screening suggests hearing loss, clinicians should obtain or refer to a clinician who can obtain an audiogram. (KAS 8) Clinicians should offer, or refer to a clinician who can offer, appropriately fit amplification to patients with ARHL. (KAS 9) Clinicians should refer patients for an evaluation of cochlear implantation candidacy when patients have appropriately fit amplification and persistent hearing difficulty with poor speech understanding. The GDG made recommendations for the following KASs: (KAS 1) Clinicians should screen patients aged 50 years and older for hearing loss at the time of a health care encounter. (KAS 2) If screening suggests hearing loss, clinicians should examine the ear canal and tympanic membrane with otoscopy or refer to a clinician who can examine the ears for cerumen impaction, infection, or other abnormalities. (KAS 3) If screening suggests hearing loss, clinicians should identify sociodemographic factors and patient preferences that influence access to and utilization of hearing health care. (KAS 5) Clinicians should evaluate and treat or refer to a clinician who can evaluate and treat patients with significant asymmetric hearing loss, conductive or mixed hearing loss, or poor word recognition on diagnostic testing. (KAS 6) Clinicians should educate and counsel patients with hearing loss and their family/care partner(s) about the impact of hearing loss on their communication, safety, function, cognition, and quality of life. (KAS 7) Clinicians should counsel patients with hearing loss on communication strategies and assistive listening devices. (KAS 10) For patients with hearing loss, clinicians should assess if communication goals have been met and if there has been improvement in hearing‐related quality of life at a subsequent health care encounter or within 1 year. The GDG offered the following KAS as an option: (KAS 11) Clinicians should assess hearing at least every 3 years in patients with known hearing loss or with reported concern for changes in hearing.

show abstract

Section: Health Care Burden Epidemiologymentioning

confidence: 99%

Clinical Practice Guideline: Age‐Related Hearing Loss Executive Summary

Tsai Do,

Bush,

Weinreich

et al. 2024

Otolaryngol.--head neck surg.

View full text Add to dashboard Cite

show abstract

“…3 For hearing health care research, sociodemographic data have rarely been collected and reported; when these data have been reported, the samples are often not representative of the patient population. 4,5 Successful recruitment and retention of a study sample that is representative of the patient population begins at the research protocol design phase. 6 Recruitment strategies to target historically underrepresented patient populations vary in degree of success by location, intervention type, and study design.…”

Section: Introductionmentioning

confidence: 99%

Demographic Representation in Clinical Research Relative to a Cochlear Implant Patient Population

Nix,

Davis,

Brown

et al. 2024

The Laryngoscope

View full text Add to dashboard Cite

ObjectivesResearch samples that are representative of patient populations are needed to ensure the generalizability of study findings. The primary aim was to assess the efficacy of a study design and recruitment strategy in obtaining a participant sample that was representative of the broader cochlear implant (CI) patient population at the CI center. A secondary aim was to review whether the CI recipient population was representative of the state population.MethodsDemographic variables were compared for a research participant sample (n = 79) and the CI patient population (n = 338). The participant sample was recruited from the CI patient population. The study design included visits that were at the same location and frequency as the recommended clinical follow‐up intervals. The demographics for the combined group (participant sample and patient population) were then compared to the reported demographics for the population in North Carolina.ResultsThere were no significant differences between the participant sample and patient population for biological sex, age at implantation, racial distribution, socioeconomic position, degree of urbanization, or drive time to the CI center (p ≥ 0.086). The combined CI recipient population was significantly different from the North Carolina population for the distributions of race, ethnicity, and degree of urbanization (p < 0.001).ConclusionThe study design and recruitment strategy allowed for recruitment of a participant sample that was representative of the CI patient population. Disparities in access to cochlear implantation persist, as supported by the significant differences in the combined CI recipient population and the population for our state.Level of Evidence3 Laryngoscope, 2024

show abstract

Clinical Practice Guideline: Age‐Related Hearing Loss

Tsai Do,

Bush,

Weinreich

et al. 2024

Otolaryngol.--head neck surg.

View full text Add to dashboard Cite

ObjectiveAge‐related hearing loss (ARHL) is a prevalent but often underdiagnosed and undertreated condition among individuals aged 50 and above. It is associated with various sociodemographic factors and health risks including dementia, depression, cardiovascular disease, and falls. While the causes of ARHL and its downstream effects are well defined, there is a lack of priority placed by clinicians as well as guidance regarding the identification, education, and management of this condition.PurposeThe purpose of this clinical practice guideline is to identify quality improvement opportunities and provide clinicians trustworthy, evidence‐based recommendations regarding the identification and management of ARHL. These opportunities are communicated through clear actionable statements with explanation of the support in the literature, evaluation of the quality of the evidence, and recommendations on implementation. The target patients for the guideline are any individuals aged 50 years and older. The target audience is all clinicians in all care settings. This guideline is intended to focus on evidence‐based quality improvement opportunities judged most important by the guideline development group (GDG). It is not intended to be a comprehensive, general guide regarding the management of ARHL. The statements in this guideline are not intended to limit or restrict care provided by clinicians based on their experience and assessment of individual patients.Action StatementsThe GDG made strong recommendations for the following key action statements (KASs): (KAS 4) If screening suggests hearing loss, clinicians should obtain or refer to a clinician who can obtain an audiogram. (KAS 8) Clinicians should offer, or refer to a clinician who can offer, appropriately fit amplification to patients with ARHL. (KAS 9) Clinicians should refer patients for an evaluation of cochlear implantation candidacy when patients have appropriately fit amplification and persistent hearing difficulty with poor speech understanding. The GDG made recommendations for the following KASs: (KAS 1) Clinicians should screen patients aged 50 years and older for hearing loss at the time of a health care encounter. (KAS 2) If screening suggests hearing loss, clinicians should examine the ear canal and tympanic membrane with otoscopy or refer to a clinician who can examine the ears for cerumen impaction, infection, or other abnormalities. (KAS 3) If screening suggests hearing loss, clinicians should identify sociodemographic factors and patient preferences that influence access to and utilization of hearing health care. (KAS 5) Clinicians should evaluate and treat or refer to a clinician who can evaluate and treat patients with significant asymmetric hearing loss, conductive or mixed hearing loss, or poor word recognition on diagnostic testing. (KAS 6) Clinicians should educate and counsel patients with hearing loss and their family/care partner(s) about the impact of hearing loss on their communication, safety, function, cognition, and quality of life (QOL). (KAS 7) Clinicians should counsel patients with hearing loss on communication strategies and assistive listening devices. (KAS 10) For patients with hearing loss, clinicians should assess if communication goals have been met and if there has been improvement in hearing‐related QOL at a subsequent health care encounter or within 1 year. The GDG offered the following KAS as an option: (KAS 11) Clinicians should assess hearing at least every 3 years in patients with known hearing loss or with reported concern for changes in hearing.

show abstract

Reporting of Sociodemographic Data in Cochlear Implant Clinical Trials: A Systematic Review

Cited by 10 publications

References 33 publications

Clinical Practice Guideline: Age‐Related Hearing Loss Executive Summary

Clinical Practice Guideline: Age‐Related Hearing Loss Executive Summary

Demographic Representation in Clinical Research Relative to a Cochlear Implant Patient Population

Clinical Practice Guideline: Age‐Related Hearing Loss

Contact Info

Product

Resources

About